ArticleJNCI cancer spectrum2026
Metformin use and the risk of liver cancer in a Swedish population-based cohort study.
Article in JNCI cancer spectrum, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
backgroundIt is uncertain whether medication with metformin decreases the risk of liver cancer. This study aimed to test the hypotheses that use of metformin decreases the risk of developing both main subtypes of liver cancer, that is, hepatocellular carcinoma and intrahepatic cholangiocarcinoma.
methodsThis nationwide population-based cohort study included all individuals who had dispensed anti-diabetic medications between 2005 and 2018 in Sweden, except for those with a history of viral hepatitis. We assessed the associations between metformin use and the risk of hepatocellular carcinoma and intrahepatic cholangiocarcinoma by using Cox regression, adjusted for age, sex, calendar year, smoking-related diagnoses, alcohol-related diagnoses, non-alcoholic fatty liver disease, use of non-steroidal anti-inflammatory drugs, and use of statins.
resultsAmong 744 173 participants, 526 859 (70.8%) were metformin users. During the follow-up of a median of 6.8 (maximum 13.5) years, 1622 participants developed hepatocellular carcinoma and 319 developed intrahepatic cholangiocarcinoma. Metformin use was associated with a slightly increased risk of hepatocellular carcinoma (hazard ratio [HR] = 1.15, 95% confidence interval [CI] = 1.02 to 1.30), but a decreased risk in participants with a prior diagnosis of obesity (HR = 0.56, 95% CI = 0.34 to 0.90). No statistically significant association was observed for intrahepatic cholangiocarcinoma (HR = 0.77, 95% CI = 0.59 to 1.01).
conclusionThis study found an increased risk of hepatocellular carcinoma associated with metformin use overall, while suggesting a decreased risk in individuals with obesity. No clear association was observed for intrahepatic cholangiocarcinoma.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.